<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Acquired pure megakaryocytic <z:mpath ids='MPATH_58'>aplasia</z:mpath> is a <z:e sem="disease" ids="C0678236" disease_type="Disease or Syndrome" abbrv="">rare disorder</z:e> defined by severe <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> with no other hematologic abnormalities and absent, or severely decreased marrow megakaryocytes </plain></SENT>
<SENT sid="1" pm="."><plain>The etiology may be immune suppression of megakaryocyte development </plain></SENT>
<SENT sid="2" pm="."><plain>Two patients are described who both responded rapidly to a combination of antithymocyte globulin and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> and who remain in remission 13-20 months after discontinuation of <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>This regimen is well described for treatment of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and may also be effective for acquired pure megakaryocytic <z:mpath ids='MPATH_58'>aplasia</z:mpath> </plain></SENT>
</text></document>